Bupivacaine HCl是一种NMDA受体抑制剂，可阻断钠通道、L-型钙通道及钾通道；该药物通过与钠通道胞内结构域结合阻断神经细胞钠离子内流，适用于慢性疼痛及心律失常的研究。
| 英文别名 (English Synonym) | Bupivacaine HCl |
| 中文名称 (Chinese Name) | 盐酸布比卡因 |
| 靶点 (Target) | Sodium Channel |
| 通路 (Pathway) | Membrane Transporter/Ion Channel |
| CAS号 (CAS NO.) | 18010-40-7 |
| 分子式 (Formula) | C18H28N2O·HCl |
| 分子量 (Molecular Weight) | 324.89 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于DMSO |
-25~-15℃保存，有效期3年
[1] Chu CR, Izzo NJ, Papas NE, Fu FH. In vitro exposure to 0.5% bupivacaine is cytotoxic to bovine articular chondrocytes. Arthroscopy. 2006 Jul;22(7):693-9. doi: 10.1016/j.arthro.2006.05.006. PMID: 16843803.[2]Sztark F, Malgat M, Dabadie P, Mazat JP. Comparison of the effects of bupivacaine and ropivacaine on heart cell mitochondrial bioenergetics. Anesthesiology. 1998 May;88(5):1340-9. doi: 10.1097/00000542-199805000-00026. PMID: 9605695.[3]Irwin W, Fontaine E, Agnolucci L, Penzo D, Betto R, Bortolotto S, Reggiani C, Salviati G, Bernardi P. Bupivacaine myotoxicity is mediated by mitochondria. J Biol Chem. 2002 Apr 5;277(14):12221-7. doi: 10.1074/jbc.M108938200. Epub 2002 Jan 14. PMID: 11790774.[4]Zhou W, Arrabit C, Choe S, Slesinger PA. Mechanism underlying bupivacaine inhibition of G protein-gated inwardly rectifying K+ channels. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6482-7. doi: 10.1073/pnas.111447798. Epub 2001 May 15. PMID: 11353868; PMCID: PMC33494.[5]Butterworth JF 4th, Brownlow RC, Leith JP, Prielipp RC, Cole LR. Bupivacaine inhibits cyclic-3',5'-adenosine monophosphate production. A possible contributing factor to cardiovascular toxicity. Anesthesiology. 1993 Jul;79(1):88-95. doi: 10.1097/00000542-199307000-00014. Erratum in: Anesthesiology 1994 Jan;80(1):250. PMID: 8393632.[6]Zink W, Graf BM, Sinner B, Martin E, Fink RH, Kunst G. Differential effects of bupivacaine on intracellular Ca2+ regulation: potential mechanisms of its myotoxicity. Anesthesiology. 2002 Sep;97(3):710-6. doi: 10.1097/00000542-200209000-00026. PMID: 12218539.
